Traduction de «nrt patch 8-week » (Français → Néerlandais) :

2000 € Minimal counselling by a GP consists of one or two consultations with a total length of 12 minutes, not provided as part of a consultation for other health reasons Minimal counselling+NRT is provided for a period of 8 weeks Intensive counselling+NRT is provided by a trained lung nurse for a total of 90 minutes after a brief advice from a lung physician, period of NRT is 12 weeks Intensive counselling+Buproprion included intensive counselling as described above with Buproprion for a period of 9 weeks Telephone counselling consists of one intake call of 30 minutes and six follow-up calls of each 15 minutes Costs of self-help materials was included One defined daily dose (DDD) equals 14 mg for NRT patches.
2000 € Minimal counselling by a GP consists of one or two consultations with a total length of 12 minutes, not provided as part of a consultation for other health reasons Minimal counselling+NRT is provided for a period of 8 weeks Intensive counselling+NRT is provided by a trained lung nurse for a total of 90 minutes after a brief advice from a lung physician, period of NRT is 12 weeks Intensive counselling+bupropion included intensive counselling as described above with bupropion for a period of 9 weeks Telephone counselling consists of one intake call of 30 minutes and six follow-up calls of each 15 minutes Costs of self-help materials was included One defined daily dose (DDD) equals 14 mg for NRT patches.

2000 US$ Average retail price of NRT gum (12-week course): US$218.78 Average retail price of NRT patch (8-week course): US$154.36 Average retail price of Buproprion (8-week course): US$201.39 Pharmacist time (5 hours of intervention, US$35/hr): US$175 Technician support (2 hours, US$5/hr): US$10 Material costs: US$5 0%
2000 US$ Average retail price of NRT gum (12-week course): US$218.78 Average retail price of NRT patch (8-week course): US$154.36 Average retail price of bupropion (8-week course): US$201.39 Pharmacist time (5 hours of intervention, US$35/hr): US$175 Technician support (2 hours, US$5/hr): US$10 Material costs: US$5 0%

Markov model Switzerland Third party payer Counselling alone Counselling+NRT gum Counselling+NRT patch Counselling+NRT spray Counselling+NRT inhaler Counselling+Buproprion Population: smokers who consume 20 cigarettes per day Study supported by Swiss Federal Office for Public Health
Markov model Switzerland Third party payer Counselling alone Counselling+NRT gum Counselling+NRT patch Counselling+NRT spray Counselling+NRT inhaler Counselling+bupropion Population: smokers who consume 20 cigarettes per day Study supported by Swiss Federal Office for Public Health

Treatment (both NRT and Buproprion) lasts at least 1 month Retail price of NRT gum: not reported Retail price of NRT patch (3-month course): €354.54 (€, 2001) Retail price of NRT nasal spray (3-months course): €743.02 3% (range 0-5% in sensitivity analysis)
Treatment (both NRT and bupropion) lasts at least 1 month Retail price of NRT gum: not reported Retail price of NRT patch (3-month course): €354.54 (€, 2001) Retail price of NRT nasal spray (3-months course): €743.02 3% (range 0-5% in sensitivity analysis)

Spontaneous cessation rate: 2.5% OR counselling only: 1.73 Incremental OR NRT gum (relative to counselling only): 1.63 Incremental OR NRT patch (relative to counselling only): 1.79 Incremental OR NRT spray (relative to counselling only): 2.35 Incremental OR NRT inhaler (relative to counselling only): 2.14 Incremental OR Buproprion (relative to counselling only): 2.30 % of smokers still under treatment after the first month: 50% (range 40-60% in sensitivity analysis) % of smokers still under treatment after the second month: 20% (range 15-25% in sensitivity analysis) Lifetime relapse probability after one year of abstinence: 35% (range 10-50% in sensitivity analysis) Effect of smoking cessation on mortality derived from the results of the American Cancer Society Prevention Study II. The mortality rate for former smokers was projected by calculating a weighted average of the incremental differentials between mortality rates of neversmokers and smokers, weighted according to the duration of abstinence.
Spontaneous cessation rate: 2.5% OR counselling only: 1.73 Incremental OR NRT gum (relative to counselling only): 1.63 Incremental OR NRT patch (relative to counselling only): 1.79 Incremental OR NRT spray (relative to counselling only): 2.35 Incremental OR NRT inhaler (relative to counselling only): 2.14 Incremental OR bupropion (relative to counselling only): 2.30 % of smokers still under treatment after the first month: 50% (range 40-60% in sensitivity analysis) % of smokers still under treatment after the second month: 20% (range 15-25% in sensitivity analysis) Lifetime relapse probability after one year of abstinence: 35% (range 10-50% in sensitivity analysis) Effect of smoking cessation on mortality derived from the results of the American Cancer Society Prevention Study II. The mortality rate for former smokers was projected by calculating a weighted average of the incremental differentials between mortality rates of neversmokers and smokers, weighted according to the duration of abstinence.

Pharmacist counselling alone 190 25% 25% Pharmacist counselling+NRT patch 344.36 25% 35% Pharmacist counselling+NRT gum 408.78 25% 20% Pharmacist counselling+Buproprion 391.39 25% 20%
Pharmacist counselling alone 190 25% 25% Pharmacist counselling+NRT patch 344.36 25% 35% Pharmacist counselling+NRT gum 408.78 25% 20% Pharmacist counselling+bupropion 391.39 25% 20%

Decision analytic model (time horizon 1 year) US Payer (third party payer or patient) Pharmacist advice alone Pharmacist advice+NRT patch Pharmacist advice+NRT gum Pharmacist advice+Buproprion Study funded by an American Pharmaceutical Association Foundation Incentive Grant
Decision analytic model (time horizon 1 year) US Payer (third party payer or patient) Pharmacist advice alone Pharmacist advice+NRT patch Pharmacist advice+NRT gum Pharmacist advice+bupropion Study funded by an American Pharmaceutical Association Foundation Incentive Grant